PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia

Inclusion Criteria: * Diagnosis of schizophrenia as defined by DSM-5 criteria. * Clinically stable schizophrenia, as evidenced by the investigator evaluation, outpatient status for at least 30 days prior to screening, and confirmation of stability by a caregiver who has regular supportive contact with the subject. * Otherwise healthy on the basis of physical examination. * Body mass index (BMI) between 18 and 35 kg/m\^2 and weight of at least 49.9 kg at screening. Exclusion Criteria: * Subjects taking any oral risperidone product (except the test doses of 0.25 mg of risperidone); or subjects taking any risperidone or 9-hydroxyrisperidone sustained-release or depot formulation within 120 days prior to study screening; or subjects who have received the 3-month depot formulation of 9-hydroxyrisperidone within 2 years of study screening. * Subjects taking a clinically relevant inducer or inhibitor of cytochrome P450 (CYP) 2D6, or CYP3A4, who have not undergone proper washout (minimum of 5 half-lives of the medication) of this prohibited medication prior to Day 1. * Medications, which in the opinion of the Investigator in conjunction with the medical monitor, may be expected to significantly interfere with metabolism or excretion of risperidone and/or 9-hydroxyrisperidone; may be associated with a significant drug interaction with risperidone; or may pose a significant risk to a subject's participation in the study. * Any natural products or herbal preparations including all vitamins and supplements throughout the study. * Subjects with a history of cancer unless disease-free for ≥5 years (with the exception of resected basal cell or squamous cell carcinoma of the skin). * Subjects with any other active medical condition/disorder/disease that may either compromise subject safety or interfere with the safety and/or outcome evaluation of the study drug. * Subjects that had an exacerbation of schizophrenia in the last 30 days. * Subjects with evidence or history (in the past 6 months prior to screening) of a significant hepatic disorder that may either compromise subject safety or interfere with the safety and/or outcome evaluation of the study drug, including: * Acute or chronic hepatitis, including but not limited to hepatitis B or C. * Total bilirubin \>1.5 x the upper limit of normal (ULN), or * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2x ULN. * Subjects with a history of severe renal disease, or creatinine clearance \<60 mL/min * Subjects with evidence or history of orthostatic hypotension within 6 months of screening. * Subjects with absolute neutrophil count \<1.5x 10\^9/L (African and African/American \<1.2x 10\^9/L). * Subjects with a history of drug-induced leucopenia. * Subjects who have acquired immune deficiency syndrome (AIDS) or to be human immunodeficiency virus (HIV)-positive. * Subjects with other medical conditions including, but not limited to, history of heart attack (myocardial infarction) or brain injury (traumatic injury with loss of consciousness and/or cerebrovascular accident), or clinically significant low blood pressure or arrhythmias as interpreted by the Principal Investigator or medically qualified sub-investigator. * Subjects with congenital long QT syndrome, history of prolonged QT in the 3 months prior to screening, or a corrected QT interval (Fridericia - QTcF) \>450 msec (male) or \>470 msec (female) at screening (Visit 1). * Subjects with suicidal ideation with intent or plan * Subjects with uncontrolled depression, in the opinion of the Investigator. * Subjects with a diagnosis of insulin-dependent diabetes, or who have a hemoglobin A1c (HbA1c) ≥8.0% at screening, or have had changes in diabetic medication regimen in the 28 days prior to signing the informed consent document. * Subjects with prior allergic reactions, sensitivities or other known contraindications to any component of RBP-7000 (e.g., risperidone, PLGH or NMP). * Women of childbearing potential who are pregnant or breastfeeding, seeking pregnancy, or failing to use adequate contraceptive methods during the study. * Subjects with the presence of opioids, cocaine, amphetamines, methadone, barbiturates, benzodiazepines, methamphetamines, cannabinoids, or phencyclidine in the urine as assessed by a urine drug screen. * Subjects with epilepsy or other seizure disorders, Parkinson's disease or dementia.